Antabuse contains disulfiram and is used in adults with alcohol use disorder when abstinence has been agreed. It inhibits aldehyde dehydrogenase, helping deter alcohol use by causing an unpleasant reaction if alcohol is consumed. The regimen is confirmed with a healthcare professional before treatment begins.
Disulfiram, the active ingredient of Antabuse, is an aldehyde dehydrogenase inhibitor used to support abstinence in adults with alcohol use disorder.
Disulfiram is used as part of alcohol-dependence treatment when abstinence has been agreed and the patient understands the consequences of alcohol exposure.
Disulfiram inhibits aldehyde dehydrogenase, so acetaldehyde can accumulate when alcohol is consumed. The disulfiram–alcohol reaction results from acetaldehyde accumulation. It can occur after drinking beer, wine, spirits, or products containing smaller quantities of ethanol. The reaction may begin within minutes and can become severe during the first hour.
The FDA describes the reaction as potentially serious, with cardiovascular complications possible in severe cases [2].
This medication is not for you if you have:
Disulfiram should not be combined with metronidazole unless a specialist has expressly directed the combination. The interaction can increase the risk of confusion, psychotic symptoms, and other serious neuropsychiatric effects. This warning applies to metronidazole taken by mouth, injection, or other systemic routes.
Other interaction concerns include:
Pregnancy and breastfeeding require an individual risk assessment. Disulfiram should not be selected casually when safer treatment options may be available, and the prescriber needs to know about pregnancy, planned pregnancy, or breastfeeding before the regimen is confirmed.
Antabuse may not be right for you if you have heart or liver problems, a history of psychosis, are currently intoxicated, or cannot reliably avoid alcohol. Tell the prescriber about all medicines, pregnancy or breastfeeding, and any recent alcohol exposure before treatment starts.
Disulfiram can cause adverse effects without alcohol exposure. The most frequently reported problems include tiredness, headache, drowsiness, metallic or garlic-like taste, unpleasant breath, nausea, and skin reactions. Some people experience reduced concentration during the early phase of treatment.
Longer exposure can affect the liver or peripheral nerves. The British National Formulary and regulatory prescribing information describe the need for clinical monitoring when disulfiram is used beyond a short period. Liver injury may develop with few early symptoms, so blood tests arranged by the prescriber can be useful during treatment [3].
Possible warning signs include:
Peripheral neuropathy may feel like pins and needles, burning, altered sensation, or weakness in the feet and hands. Optic neuritis is uncommon but can affect vision. New neurological or visual symptoms should prompt urgent contact with the prescriber rather than waiting for a routine appointment.
Disulfiram may also cause drowsiness. Alcohol-related exposure can intensify its effects, while taking additional sedating medicines may worsen impaired alertness. Patients who notice reduced coordination should avoid driving and machinery until the effect has been assessed.
Antabuse contains disulfiram, a medicine from the aldehyde dehydrogenase inhibitor class. The product is supplied as tablets, with 50 tablets in the pack. Disulfiram is used as part of alcohol-dependence treatment when abstinence has been agreed and the patient understands the consequences of alcohol exposure.
The medicine does not remove alcohol cravings through opioid or dopamine receptor blockade. Its main role is deterrence: alcohol taken during treatment can produce a rapid and unpleasant physical reaction. The U.S. Food and Drug Administration prescribing information describes disulfiram as an aid in maintaining abstinence, rather than a standalone cure for alcohol use disorder [1].
After alcohol enters the body, alcohol dehydrogenase converts it into acetaldehyde. Aldehyde dehydrogenase then helps convert acetaldehyde into acetate, which is less biologically disruptive. Disulfiram inhibits aldehyde dehydrogenase, so acetaldehyde can accumulate when alcohol is consumed.
The treatment depends on adherence. A tablet cannot prevent drinking by itself, and it does not treat withdrawal symptoms safely. Starting disulfiram while a person is still intoxicated or physically dependent on alcohol requires careful clinical management because alcohol withdrawal can cause seizures, delirium, and other urgent complications. Follow-up can help identify adherence problems early. Psychosocial support remains part of treatment.
Antabuse is taken by mouth as tablets. The regimen for the chosen strength is confirmed with a healthcare professional before treatment begins. The regimen may be adjusted according to treatment response, liver function, age, other medicines, and the level of supervision available.
A missed dose should not be replaced with an improvised extra dose. The patient should use the missed-dose instruction supplied by the prescribing service, especially when the next scheduled dose is close. Double dosing can increase adverse effects without improving protection from alcohol.
Antabuse creates a behavioural barrier by changing alcohol metabolism. Other medicines act through opioid receptors, glutamate signalling, or broader effects on brain excitability. The most suitable option depends on drinking pattern, liver and kidney function, opioid exposure, seizure risk, pregnancy status, and treatment goals.
| Treatment | Main pharmacological approach | Typical clinical role |
|---|---|---|
| Antabuse | Disulfiram inhibits aldehyde dehydrogenase | Supports abstinence through an alcohol reaction |
| Naltrexone | Opioid-receptor antagonism | Can reduce alcohol reward and heavy-drinking days |
| Acamprosate | Modulates glutamate and GABA balance | Supports abstinence after detoxification |
| Topiramate | Neuromodulatory effects on excitatory signalling | An adjunct option in selected patients |
Naltrexone is unsuitable for people using opioid analgesics because it can block opioid effects and precipitate withdrawal. Liver status also matters. Acamprosate is cleared mainly through the kidneys and may suit some patients whose liver function limits other options.
Topiramate is not interchangeable with disulfiram. It can cause cognitive slowing, tingling, appetite changes, and other neurological effects. The combination of naltrexone and bupropion in Contrave is authorised for weight management, not as a routine treatment for alcohol use disorder; Contrave should not be treated as a substitute for an alcohol-dependence medicine.
The WHO recognises medication as one component of alcohol-use-disorder care, alongside psychosocial treatment, relapse planning, and management of physical and mental health conditions [4]. The advantage of disulfiram is its clear deterrent mechanism. Its limitation is equally clear: it requires reliable alcohol avoidance and does not suit a person who cannot maintain that boundary.
Several avoidable errors reduce the benefit of treatment or increase risk:
A common misunderstanding is that the reaction happens only with spirits. Beer, wine, mixed drinks, and ethanol-containing products can also trigger it. Another is that the reaction ends as soon as vomiting stops; low blood pressure, arrhythmia, or breathing problems may persist and require emergency assessment.
In clinical practice, prescribers often describe disulfiram as a commitment-based treatment. It works best when the patient understands the reaction, has a realistic alcohol-avoidance plan, and receives regular follow-up. Supervised dosing may be considered when adherence is uncertain or when family-supported treatment is appropriate.
A physician will usually distinguish alcohol withdrawal from the effects of Antabuse. Tremor, sweating, agitation, hallucinations, confusion, and seizures after stopping heavy drinking may represent withdrawal, not a routine medicine side effect. Severe withdrawal can be life-threatening and needs urgent medical care.
Liver monitoring is not a formality. A patient with new fatigue, jaundice, abdominal discomfort, or dark urine may need prompt assessment before the next dose. Neurological symptoms also deserve early review because peripheral nerve damage may become harder to reverse when recognised late.
One practical issue is hidden alcohol. Patients may remember spirits and forget cough mixtures, alcohol-based mouthwash, or cooking extracts. A clinician will usually ask about these exposures directly rather than assuming that abstinence means only avoiding drinks.
Tiredness and drowsiness are recognised effects of disulfiram, and the FDA prescribing information dated 2001 lists these among possible adverse reactions. MHRA safety information available in 2024 also supports caution with activities requiring alertness. Avoid driving or machinery if you feel slowed, dizzy, or unusually sleepy.
Yellowing of the skin, dark urine, severe abdominal pain, new vision changes, marked numbness, fainting, chest pain, breathing difficulty, or confusion need urgent medical assessment. The FDA prescribing information from 2001 identifies liver, neurological, cardiovascular, and psychiatric symptoms as clinically significant concerns. Do not take another dose while waiting for urgent instructions if a severe reaction or suspected liver injury has developed.
The most important habit is complete avoidance of alcohol, including ethanol in some liquid medicines and personal-care products. NHS alcohol-dependence guidance from 2023 supports combining medicine with structured recovery support, stable routines, and relapse planning. Regular meals, sleep, hydration, and suitable physical activity may support recovery, while using alcohol to manage stress directly undermines the treatment goal.
Disulfiram is not generally withdrawn through a gradual taper in the same way as some antidepressants or sedatives. The NHS treatment framework in 2022 stresses that the risk of an alcohol reaction can continue after the last dose because disulfiram’s effect may persist. Alcohol should still be avoided after stopping until the prescriber confirms that the reaction risk has passed.
Older adults may be more vulnerable to dizziness, falls, drowsiness, liver problems, and interactions with several medicines. Guidance from the Royal College of Psychiatrists published in 2020 supports a slower, more closely monitored approach when multiple medicines or physical illnesses are present. The prescribing clinician may review liver function, kidney health, cognition, mobility, and the complete medicine list before confirming treatment.
Antabuse changes alcohol metabolism by inhibiting aldehyde dehydrogenase, while naltrexone blocks opioid receptors involved in alcohol reward. NICE guidance from 2011, updated in 2014, describes these as different pharmacological approaches with different suitability criteria. Naltrexone can be unsuitable during opioid treatment, whereas disulfiram is unsuitable when reliable alcohol avoidance cannot be maintained.
Disulfiram may cause drowsiness, fatigue, dizziness, headache, or reduced concentration in some patients. The MHRA driving-safety principles published in 2025 require the individual response to be considered before driving or operating machinery. A person should stop the activity if alertness, coordination, vision, or reaction time feels impaired.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I used the tablets after discussing the regimen with my doctor. The first week involved a metallic taste and more tiredness than expected, but the clear alcohol warning helped me stay focused.
I took Antabuse. It made me more careful about cough medicine and mouthwash, which I had never considered before. Concentration felt poorer in the afternoons, so I stopped driving until it settled.
The treatment supported my decision to remain alcohol-free, and my family found the plan easier to understand. I disliked the dry mouth and attended the blood tests arranged by my clinic.
I missed a tablet and nearly took two the next morning. The prescribing team told me not to improvise the dose. That was useful because I had assumed doubling would restore protection.
I developed tingling in my feet during treatment. It was not dramatic at first, but the doctor wanted it assessed promptly. The medicine was reviewed rather than simply continued.
